Skip to main content
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
December 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Subscribe
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
December 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
ASCO 2017 - Chronic Lymphocytic Leukemia
ASCO 2017 - Chronic Lymphocytic Leukemia
Phase 1 Dose Escalation of Ibrutinib and Buparlisib in Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Mantle-Cell Lymphoma, and Follicular Lymphoma
Read More
ASCO 2017 - Chronic Lymphocytic Leukemia
KI Intolerance Study: A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with CLL Intolerant to Prior Bruton’s Tyrosine Kinase or PI3Kδ Inhibitor Therapy
Read More
ASCO 2017 - Chronic Lymphocytic Leukemia
iFCG for Previously Untreated Patients with CLL with Mutated IGHV and Non-Del(17p)
Read More
ASCO 2017 - Chronic Lymphocytic Leukemia
Results of a Phase 2 Multicenter Study of Obinutuzumab plus Bendamustine in Patients with Previously Untreated CLL
Read More
ASCO 2017 - Chronic Lymphocytic Leukemia
CD19 CAR T-Cells Combined with Ibrutinib to Induce Complete Remission in CLL
Read More
ASCO 2017 - Chronic Lymphocytic Leukemia
Combination Ibrutinib and Venetoclax for the Treatment of MCL: Primary End Point Assessment of the Phase 2 AIM Study
Read More
ASCO 2017 - Chronic Lymphocytic Leukemia
A Phase 1a/1b Study of a Novel BTK Inhibitor and Combination Products with Everolimus and Pomalidomide in Patients with CLL or Other B-Cell Lymphomas
Read More
ASCO 2017 - Chronic Lymphocytic Leukemia
Phase 3 Study of the Bruton’s Tyrosine Kinase Inhibitor, Ibrutinib, in Combination with Rituximab versus Placebo in Combination with Rituximab in Patients with TN FL (PERSPECTIVE)
Read More
ASCO 2017 - Chronic Lymphocytic Leukemia
Tolerability and Activity of the Chemotherapy-Free Triplet TGR-1202, Ublituximab, and Ibrutinib in Patients with Advanced CLL and NHL
Read More
ASCO 2017 - Chronic Lymphocytic Leukemia
Randomized, Double-Blind Phase 3 Study of Ibrutinib versus Placebo in Combination with Corticosteroids in Patients with New-Onset cGVHD
Read More
1
2
Page 1 of 2
Results 1 - 10 of 16